 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12345678910111213...8687» |
- Effects of different antiresorptive treatment on medication-related osteonecrosis of the jaw in patients undergoing dental procedures: A systematic review and network meta-analysis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1451;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab and denosumab combination therapy in post-menopausal osteoporosis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1450;
- Bone Health in Nursing Home Residents in Germany (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1436;
- Effects of RANKL inhibition on osteotomy healing in a murine model of fibrous dysplasia (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1246;
- Concurrent Treatment with Teriparatide, Estrogen and Thiazides Result in Extremely Large One-Year Gains in BMD (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1165;
- Prolia (denosumab) / Amgen
Outcomes in Cancer Patients on Denosumab 120 mg/month on Utilization of a Unique Pharmacy-driven Home Injection Service Program as Part of a Multi-disciplinary Team (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1127;
- Fracture Rates for Patients Living with Osteogenesis Imperfecta (OI): Real-world Results from US Retrospective Claims (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1088;
- raloxifene hydrochloride / Generic mfg.
Trends in the Use of Raloxifene for Osteoporosis, 1999-2022 (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1046;
- Prolia (denosumab) / Amgen
Denosumab Discontinuation and the Rebound Phenomenon: A Case Report (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1045;
- Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among Postmenopausal Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies in the US (2019 (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1040;
- Exploring Risk Factors and Time-To-Onset Antiresorptive Drug-induced Osteonecrosis of the Jaw (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1039;
- The use of 3D-DXA cortical and trabecular parameters in combination with areal bone mineral density better captures responders to osteoporosis drug treatments (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1038;
- Prolia (denosumab) / Amgen
Assessing for Risk Factors for Medication-Related Osteonecrosis of the Jaw in Men and Women Prescribed Bisphosphonates or Denosumab for Fracture Prevention (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1034;
- Prolia (denosumab) / Amgen
Use of bisphosphonates to prevent bone loss with denosumab discontinuation: observations from clinical practice (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1033;
- Prolia (denosumab) / Amgen
Bone Mineral Density Changes in Postmenopausal Women Switching from 30 mg Denosumab to Intravenous Zoledronic Acid: A Prospective Observational Study (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1030;
- Treatment-related changes in total hip bone mineral density and fracture risk reduction for trials with active control and sequential therapy: the FNIH-ASBMR-SABRE Project (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1028;
- Prolia (denosumab) / Amgen
Identification and Classification of Periprosthetic Fractures with Atypical Features among Bisphosphonate (BP) and Denosumab Exposed Patients with Prior Total Hip Arthroplasties: Findings from a Veterans Health Administration Cohort (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1013;
- Association of Bone Mineral Density (BMD) and Hip Fracture Risk among Asian and non-Hispanic White Women in a Western US Healthcare Population (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_1008;
- Association of Serum Pentosidine and Atypical Femur Fractures: a Case-Control Study (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_891;
- ALP as a surrogate marker for estimating bone turnover in hemodialysis patients (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_748;
- Prolia (denosumab) / Amgen
Treatment of 1,25-D mediated Hypercalcemia and Extraosseous Giant Cell Tumor in Paget Disease of Bone with Denosumab (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_739;
- Cohort profile : Health Outcome of Hyperparathyroidism Evolvement (HOPE) cohort (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_733;
- Prolia (denosumab) / Amgen
Oscillating Episodes of Hypocalcemia and Hypercalcemia in a Prostate Cancer Patient Undergoing Intermittent Denosumab Therapy (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_731;
- Prolia (denosumab) / Amgen
Denosumab for the Treatment of Aneurysmal Bone Cyst in a 10-Year-Old Boy (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_713;
- Prolia (denosumab) / Amgen
Denosumab Discontinuation - Clinical Experience (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_711;
- Comparison of the role of bone turnover markers P1NP, CTX and NTX and safety in patients on antiresorptive therapy undergoing dental extractions. (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_664;
- Efficacy of Anti-Osteoporosis Therapy in Women Under and Over Age 75: an Analysis of the FNIH-ASBMR-SABRE Database (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_647;
- Factors associated with BMD response to 1-year treatment with anti-osteoporotic medications in osteoporosis management (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_646;
- How to Manage Paget's Disease of Bone (PDB) in a Patient with Chronic Kidney Disease (CKD)? (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_600;
- Disability, functional limitation, and use of anti-fracture drug therapies in a cohort of 3651 U.S. adults with osteogenesis imperfecta (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_564;
- Treatment-related changes in total hip bone mineral density and fracture risk reduction for trials with active control and sequential therapy: the FNIH-ASBMR-SABRE Project (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_551;
- Effects of different antiresorptive treatment on medication-related osteonecrosis of the jaw in patients undergoing dental procedures: A systematic review and network meta-analysis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_548;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab and denosumab combination therapy in post-menopausal osteoporosis (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_546;
- Association of Bone Mineral Density (BMD) and Hip Fracture Risk among Asian and non-Hispanic White Women in a Western US Healthcare Population (Discovery Hall, Exhibit Hall E, 800 Level South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_542;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Potent suppression of bone remodeling by denosumab does not blunt the anabolic response to romosozumab in mice (Meeting Room 714/716 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_405;
- Prolia (denosumab) / Amgen, Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
A Comparative Study of the Effects of 12-Month Romosozumab Treatment versus Sequential Treatment with 6 Months of Romosozumab Followed by Denosumab in Korean population: A Multi-center Retrospective Study (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_355;
- Prolia (denosumab) / Amgen
Denosumab Increases Bone Mass in Postmenopausal Women and Older Men Undergoing Bariatric Surgery: A Randomized Controlled Trial (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_332;
- Prolia (denosumab) / Amgen
Efficacy and Safety of Zoledronate, Denosumab and Teriparatide In Postmenopausal Women with Type 2 Diabetes Mellitus at High-Risk of Fragility Fractures: Results from a Randomized Pilot Trial (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_331;
- Proteomic Analysis of Bone from Ovariectomized Cynomolgus Monkeys Treated with Antiresorptive Agents Shows Differential Regulation of Cholesterol Metabolism (Meeting Room 718 South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_288;
- Prolia (denosumab) / Amgen
Denosumab Withdrawal (Meeting Room 713A South) - Aug 5, 2024 - Abstract #ASBMR2024ASBMR_215;
- | Prolia (denosumab) / Amgen
Journal, Real-world evidence, Real-world: A Real-world Study of Denosumab For Reducing Refracture Risk after Percutaneous Vertebral Augmentation. (Pubmed Central) - Aug 1, 2024
Continued denosumab treatment after PVA is associated with a lower risk of osteoporotic and clinical vertebral fractures. Therefore, denosumab may be a treatment option for patients with osteoporosis after PVA.
- Mycobutin (rifabutin) / Pfizer, Lupin, Prolia (denosumab) / Amgen, Lamprene (clofazimine) / Novartis
HYPERCALCEMIC CRISIS DUE TO GRANULOMATOUS BONE MARROW INFECTION: A RARE PRESENTATION OF DISSEMINATED MYCOBACTERIUM GENAVENSE IN AN IMMUNOCOMPETENT PATIENT (Convention Center Exhibit Hall: Rapid Fire Area 2B) - Jul 31, 2024 - Abstract #CHEST2024CHEST_3295;
Treatment of Mycobacterium genavense commonly includes a three-agent regimen. Further research is needed to determine an adequate treatment regimen for M. genavense.
- || Prolia (denosumab) / Amgen
Retrospective data, Review, Journal, Combination therapy: Evaluating the Clinical Efficacy of Teriparatide and Denosumab Combination Therapy in Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jul 31, 2024
However, the two groups had no evident difference in adverse reaction incidence (P > .05). The combined treatment of DEN and TPTD exhibits notable efficacy in managing PMO, warranting its promotion and use in clinical practice.
- Prolia (denosumab) / Amgen
Meet the Professor: Denosumab Withdrawal (Meeting Room 713A South) - Jul 31, 2024 - Abstract #ASBMR2024ASBMR_34;
- Prolia (denosumab) / Amgen
ASBMR/ECTS Clinical Debate: Should Denosumab Be First Line Therapy for Patients with Breast Cancer Treated with Hormonal Therapy? (Exhibit Halls F & G, 800 Level South) - Jul 31, 2024 - Abstract #ASBMR2024ASBMR_20;
- Prolia (denosumab) / Amgen
Clinical Special Session: Challenge the Expert - Denosumab: Stopping after 10 Years or Not? (Meeting Room 714/716 South) - Jul 31, 2024 - Abstract #ASBMR2024ASBMR_11;
- | Prolia (denosumab) / Amgen
Journal: Immunohistochemical expression of H3.3 G34W in 100 giant cell tumors of bone and its diagnostic mimics, including its value in resolving uncommon diagnostic scenarios: A single institutional study at a tertiary cancer referral center, India. (Pubmed Central) - Jul 30, 2024
This constitutes one of the first reports from our country, further validating the diagnostic value of H3.3 G34W in differentiating GCTB, including metastatic and malignant forms from its mimics, including small biopsy samples. Its value in various diagnostic dilemmas is presented and utility in identifying residual tumor cells in post-denosumab treated GCTBs is worth exploring.
- | Prolia (denosumab) / Amgen, Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Retrospective data, Journal, Metastases: Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy. (Pubmed Central) - Jul 29, 2024
This study highlights the potential clinical relevance of the RANK pathway in BC treatment, and our findings suggest that denosumab may offer significant benefits in terms of PFS and OS for certain subgroups, particularly those with HER2 scores of 1, patients under 60, and those with endocrine-resistant BC. In conclusion, considering that RANK pathway status may be a predictive biomarker for CDK4/6i treatment and may cause treatment resistance, our results demonstrate the clinical relevance of the combination of CDK4/6i + ET with RANKL inhibition.
- | Prolia (denosumab) / Amgen
New P1/2 trial: Denosumab for Type 1 Diabetes (clinicaltrials.gov) - Jul 28, 2024
P1/2, N=45, Recruiting, Sponsor: City of Hope Medical Center
- | Prolia (denosumab) / Amgen
Journal: Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019-2023. (Pubmed Central) - Jul 28, 2024
Osteoporosis care, indicated by medication prescriptions, also declined during the pandemic. Addressing these issues requires focused investment and effort to improve DXA scan waiting times and overall access to osteoporosis care in England.